A hospital-based prediction model identified benzodiazepine exposure among variables associated with later cognitive impairment.
The retrospective cohort included 866 sepsis patients, with cognition assessed one to three months after discharge using the Montreal Cognitive Assessment. A random-forest model incorporated age, education, illness severity, inflammatory markers, and benzodiazepine use. The authors reported strong discrimination in their study’s training and validation subsets.
Internal validation within one source population does not establish transportability to another hospital or patient group. Benzodiazepine use may mark severity or treatment need. SHAP values describe the fitted model’s behavior and do not prove a biological causal pathway.
For a cognitive-injury opinion, distinguish prediction from attribution. The model cannot determine what proportion of an individual’s deficit was caused by a sedative. Baseline cognition, illness, delirium, exposure details, and follow-up testing remain necessary before drawing a case-specific conclusion.
Source reviewed: Development and validation of an interpretable machine learning model for predicting cognitive impai (PMC12868286). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Professionals’ Benzodiazepine Goals Included Harm Reduction as Well as Abstinence; Bronchiolitis Withdrawal Model Found an Opioid Association but No Clear Benzodiazepine Association.